Danaher Corp /de/ (DHR) · Oct 13, 2026 · Exec change

Danaher board expands with former CFO, biotech scientist

Board expanded — 13 directors after two appointments

Danaher’s board expands with a former CFO and biotech scientist, while longtime director Alan Spoon plans to retire at the 2027 annual meeting.

Danaher is a science-and-technology company organized around biotechnology, life sciences, and diagnostics, while pushing deeper into tools that accelerate drug discovery and laboratory research.

The board is adding targeted expertise, not changing operating leadership. Danaher increased its board to 13 members and appointed former CFO Daniel Comas and biotech executive Robert Hershberg, with Hershberg joining the Science and Technology Committee. Comas brings deep institutional knowledge of Danaher’s finance, treasury, risk management, and acquisition history; Hershberg adds external drug-development and biotechnology experience. That combination fits the company’s current science-heavy portfolio, but it does not itself alter strategy, capital allocation, or execution.

The Comas appointment formalizes a transition that was already underway. His consulting agreement ended September 30, 2026, when he joined the board, after he earned $525,000 in 2025 and $393,750 in 2026 for strategic advice. 〔0〕 This makes the change more governance-oriented than operational: Danaher retains his institutional perspective without keeping him in an executive or consulting role.

The offset is a planned board departure, not a governance dispute. Alan Spoon will retire at the 2027 annual meeting and will not stand for re-election; the filing explicitly says the decision was not due to disagreement with Danaher. 〔1〕

Bottom line: This is a measured board refresh that strengthens finance and biotechnology coverage while preserving continuity. It matters for oversight, but it does not materially change Danaher’s business trajectory today; the market had no clean earnings-style benchmark against which to score it.

What to watch next

2027 annual meeting shareholder vote on director nominees

Original filing on SEC EDGAR

More Danaher Corp /de/ news

Danaher board expands with former CFO, biotech scientist | DHR Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.